|
|
||||||||
1From the National Research Council Canada, Ottawa, Ontario, Canada; the 2Department of Ophthalmology, Linköping University Hospital, Linköping, Sweden; the 3University of Ottawa Eye Institute, Ottawa, Ontario, Canada; the 4University of Tennessee Health Center, Memphis, Tennessee; and the 5Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
| Abstract |
|---|
|
|
|---|
METHODS. Porcine type I collagen (10%; pH 5), was mixed with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide (NHS). The final homogenous solution was molded to corneal dimensions, cured, and then implanted into rabbits and minipigs by lamellar keratoplasty. The implants were followed for up to 6 months after surgery. Clinical examinations of the cornea included detailed slit lamp biomicroscopy, in vivo confocal microscopy, topography and esthesiometry for nerve function. Histopathologic examinations were also performed on rabbit corneas harvested after 6 months.
RESULTS. Cross-linked collagen (refractive index, 1.35) had optical clarity superior to human corneas. Implanted into rabbit and porcine corneas, only 1 of 24 of the surgical corneas showed a slight haze at 6 months after surgery. All other implants showed no adverse reactions and remained optically clear. Topography showed a smooth surface and a profile similar to that of the contralateral nonsurgical eye. The implanted matrices promoted regeneration of corneal cells, tear film, and nerves. Touch sensitivity was restored, indicating some restoration of function. The corneas with implants showed no significant loss of thickness and demonstrated stable hostgraft integration.
CONCLUSIONS. Collagen can be adequately stabilized, using water soluble carbodiimides as protein cross-linking reagents, in the fabrication of corneal matrix substitutes for implantation. The simple cross-linking methodology would allow for easy fabrication of matrices for transplantation in centers where there is a shortage of corneas, or where there is need for temporary patches to repair perforations in emergency situations.
The cornea is the main refractive element of the visual system and also serves as a protective barrier. As such, corneas have several key properties that must be replicated in any artificial replacement. These include high optical clarity, appropriate refractive index, toughness to withstand surgical procedures, and nontoxicity, nonimmunogenicity and noninflammatory properties. A variety of synthetic and naturally derived materials has been used to form hydrogels for cornea tissue engineering scaffolds.4 We recently reported on corneal replacements based on collagen and the copolymer poly(N-isopropylacrylamide-co-acrylic acid-co-acryloxylsuccinimide; designated TERP).5 6 These tissue-engineered matrices were optically clear, moldable into the dimensions of human corneas, and adequately robust for implantation. When implanted into porcine corneas, they promoted regeneration of corneal cells as well as nerves. Although such matrices have the potential to be useful as corneal implants, custom synthesis of TERP would be necessary. However, collagen-TERP implant performance confirmed that collagen-based matrices are viable alternatives to donor tissues.
The human cornea comprises lamellae of mainly type I collagen (
70% dry weight) interspersed with glycosaminoglycans. Collagen I is widely available from bovine, porcine or, more recently, recombinant sources. Collagen forms robust hydrogels as a result of its semirigid-rod, triple-helix structure. However, collagen is susceptible to biodegradation by collagenases and for use in tissue repair, requires stabilization. Collagen biodegradation is retarded by chemical cross-linking with water-soluble carbodiimides (WSCs), a family of protein cross-linking reagents.7 WSCs themselves do not become incorporated as part of the final cross-links in these hydrogels, so there is no possibility of toxic substance release into tissues from subsequent cross-link breakdown.7
The objective of this study was to develop simple, cell-free, cornea-shaped matrices, based on high concentrations of collagen I cross-linked with a WSC, and to implant them so that progressive recruitment of autologous host cells would occur to make the implanted matrix both functional and integrated with the recipients tissue.
| Methods |
|---|
|
|
|---|
|
Mechanical Properties.
Suturability of the cornea-shaped implants to human corneal rims was evaluated in vitro by determining the ability of the implants to tolerate placement of 16 polyamide, monofilament sutures (Ethicon, 10-0, 33 µm), including knotting and burial of knots, without shearing or tearing. This is the same surgical procedure as that used for transplantation. Evaluation of surgical suturability in vivo on mice was determined with continuous sutures (11-0 monofilament).
For comparison with this surgical performance, hydrogel properties were measured on an Instron Tensile Testing Machine by the "suture pull out" method described previously6 also known as "suture retention testing."8
Diffusion Permeability.
Glucose diffusion permeability was determined by using the procedure of Liu and Sheardown.9 Measurements were made at 35°C (the corneas normal, physiological temperature) using a modified Ussing chamber (Warner Instruments, Hamden, CT) with air-lift mixing. Hydrogel implants (440-µm thick) were placed between the glucose permeate chamber (8 mL of 0.05 g/mL glucose in PBS) and the receptor (PBS) chamber. The receptor chamber was sampled periodically and colorimetrically analyzed at 540 nm, using a glucose assay kit (GAGO-20; glucose oxidase/peroxidase reagent and O-dianisidine dihydrochloride reagent; Sigma-Aldrich) with a spectrophotometer (UV-1601; Shimadzu, Kyoto, Japan).
For albumin diffusion permeability measurements at 35°C, a simple side-by side diffusion chamber with magnetic stirring in each chamber (PermeGear, Bethlehem, PA) was used to avoid albumin-induced foaming. FITC-labeled bovine albumin (66 kDa; Sigma-Aldrich, St. Louis, MO) was used as the tracer molecule. Both the receptor and permeate chambers were 3 mL in volume, with 50 µM albumin used in the latter chamber. Sampling was performed as in the glucose measurements. Albumin concentrations in the receptor chamber were determined by measuring the fluorescence of each sample in a fluorophotometer (Fluoro IV, Gilford, Oberlin, OH) and fitting the values to a regression line formed with standards of known concentration.
In Vitro Biocompatibility Tests
Toxicity tests were performed by NAMSA (North American Science Associates, Inc., Norwood, OH) in accordance with International Organization for Standardization (ISO) tests.10 11 12
Agarose Overlay for Cytotoxicity.
A 1-cm2 piece of EDC/NHS cross-linked collagen hydrogel, a negative control, and a positive control, were placed on each of triplicate vital stain-containing agarose surfaces directly overlying confluent monolayers of L-929 mouse fibroblast cells in 10-cm2 wells.10 After 24 hours of incubation at 37°C in a 5% CO2 environment, the cultures were evaluated for toxicity. Dead cells do not take up vital stain. Hence, the extent of unstained areas under and around the test sample gave an indication of toxicity. Cells were also examined for abnormal morphology. Cytotoxicity was graded on a scale of 0 (nonreactive or nontoxic) to 4 (severe reactivity). A positive control (latex rubber) was graded at
4, whereas a negative control (polyethylene) was graded at 0.
Genotoxicity Tests.
Bacterial reverse mutation tests were used as rapid screening procedures for determination of mutagenic and carcinogenic potential.11 Briefly, dimethyl sulfoxide (DMSO) was used to extract any leachables from the hydrogels that might cause mutagenic changes. The DMSO vehicle served as the negative control, whereas paradimethylaminobenzene diazosulphonic acid sodium (dexon), a known mutagen, served as a positive control. The extracts were tested to determine whether they was inhibitory to the growth of established histidine-dependent Salmonella typhimurium and tryptophan-dependent Escherichia coli strains. Briefly, separate tubes were loaded with 2 mL of molten agar, cooled, and supplemented with histidine-biotin solution for S. typhimurium and with tryptophan for E. coli. Separate tubes were inoculated with 0.1 mL each of five tester bacterial stains and 0.1 mL of the DMSO extract. A sterile S9 homogenate (0.5 mL) prepared from PCB (Aroclor 1254; Monsanto, St. Louis, MO)-tainted rat livers was added to each plate to induce metabolic activation. DMSO extracts and negative and positive controls were tested in triplicate, with each strain of tester bacteria.
Cytotoxicity of Extractable Materials.
To determine whether leachables extracted from collagen hydrogels would cause cytotoxicity, hydrogels were extracted using DMEM containing 5% serum and 2% antibiotics.9 Each extract was placed on a prepared L-929 cell monolayer grown in 10-cm2 well and incubated for 48 hours. Negative controls comprised extracts from polyethylene and DMEM extraction vehicle alone. Tin-stabilized polyvinylchloride served as a positive control. Toxic leachables would be expected to cause cell lysis. Grading of reactivity was done from 0, no lysis, to 4, severe lysis (i.e., causing greater than 70% lysis).
Systemic Toxicity Tests.
Collagen hydrogels were rinsed with PBS and extracted in either 0.9% sodium chloride or sesame oil. Crl:CF-1 BR mice, 18 to 22 g body weight, were injected with each extract at a dose of 50 mL/kg.12 Sodium chloride extracts were injected intravenously while sesame oil extracts were given intraperitoneally. The mice were observed for toxicity immediately after administration and at 4, 24, 48, and 72 hours.
In Vitro Performance.
Immortalized human corneal epithelial cells (HCECs)13 were used to evaluate epithelial coverage. HCECs were seeded on top of 1.5-cm2 hydrogel pieces and supplemented with a serum-free medium containing epidermal growth factor (keratinocyte serum-free medium [KSFM]; Life Technologies, Burlington, Ontario, Canada) until confluence. The medium was then switched to a serum-containing modified supplemented hormonal epithelial medium (SHEM)14 for 2 days, followed by maintenance at an airliquid interface. At 2 weeks, constructs were fixed in 4% paraformaldehyde in 0.1 M PBS and were processed for routine hematoxylin and eosin (H&E) staining. As an internal control for HCEC viability,15 growth rates of cells from each HCEC batch were also measured on tissue culture dishes (plasma-treated polystyrene) under identical culture conditions. The epithelial stratification on hydrogels was also evaluated.
To determine the ability of the hydrogels to support nerve growth, dorsal root ganglia from chick embryos (E 8.0) were attached to the surface of washed gel pieces with a collagen-based adhesive. Neurite growth was observed for up to 7 days and then fixed in 4% paraformaldehyde in PBS (pH 7.27.4) and stained at 4°C overnight for the presence of neurofilaments, by using mouse anti-NF200 antibody. Neurofilaments were visualized the following day by using donkey anti-mouse-Cy2 secondary antibody. Wholemounts were imaged by microscope (Axiovert; Carl Zeiss Meditec, Inc., Dublin, CA).
Implantation and Evaluation
Implantation.
In accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and with ethics approval from both Linköping University (Protocol 47-03) and the University of Ottawa (Protocol EI-5), matrices (350-µm-thick and 5-mm diameter, trephined from the cornea-shaped hydrogels; Fig. 1B ) were implanted into the corneas of 16 New Zealand White rabbits, 3 kg in weight, by deep lamellar keratoplasty (DLKP) with overlying sutures (Zirm retention bridge suturing).16 Before surgery and at all examinations, animals were anesthetized with intramuscular (IM) xylazine (5 mg/kg; Rompun; Bayer Leverkusen, Germany) and ketamine (30 mg/kg; Ketalar; Parke-Davis, Barcelona, Spain). Only one eye was operated on for each animalthe nonsurgical, contralateral eye being used as a positive control. DLKP was also performed on eight Göttingen minipigs using the same protocol as for rabbits, except that implants were 500-µm-thick and 6-mm in diameter. Preliminary studies of penetrating keratoplasty on mice were performed with continuous running 11-0 sutures. Corneal thicknesses were approximately 380 (rabbits), 700 (mini-pigs), and 100 (mice) µm. Animals were not given steroids, only antibiotics and analgesics during the first week after surgery. Sutures were removed at 3 weeks after surgery.
Clinical Evaluation.
Follow-ups were performed daily on each rabbit and pig for 7 days after surgery and then weekly. Examinations included slit lamp examination to ensure that corneas were optically clear, Schirmers test to assess tear film regeneration, and sodium fluorescein staining to assess integrity and barrier function. Intraocular pressure measurements were taken to ensure that implants were not blocking aqueous humor flow.
Corneal topographies were measured with a fluorescence profilometer (Par Vision Systems, New Hartford, NY) on both control and surgical eyes in the pigs before surgery and at 6 months after surgery. Average refractive powers were derived from the measured topographies of each cornea. The average power (Pave) was calculated by transforming the radius of curvature (R in meters) of the best-fit sphere from the topography into dioptric power with Pave = (n 1)/R using a refractive index (n) of 1.337.
In vivo confocal microscopic examination (ConfoScan3; Nidek, Tokyo, Japan) was used to assess cell and nerve ingrowth, as well as to measure corneal thickness in live animals. Corneal touch sensitivity was measured with a Cochet-Bonnet esthesiometer (Handaya Co., Tokyo, Japan).
Histopathologic Evaluation.
Pairs of rabbits were killed sequentially after three days, 1 week, and 1, 2, 3, and 5 months after implantation, with four animals killed at 6 months after surgery. Corneas with implants and control, nonsurgical corneas were processed for routine histopathologic examination after hematoxylin and eosin (H&E) staining.
Statistics
We tested the two-tailed hypothesis that there is either thinning or swelling of the implanted cornea over the nonsurgical contralateral controls using a paired two sample t-test for means. Statistical significance was set at P
0.05.
| Results |
|---|
|
|
|---|
|
Diffusion Permeability.
The glucose diffusion permeability coefficient for EDC/NHS cross-linked collagen hydrogels was (2.7 ± 0.8) x 106 cm2/s (n = 3 samples), whereas that of the corneal stroma was estimated to be 2.5 x 106 cm2/s.19 The albumin diffusion permeability coefficient was measured as (1.6 ± 0.6) x 107 cm2/s (n = 4 samples).
Biocompatibility Tests
Hydrogel Cytotoxicity.
Agarose overlay testing for cytotoxicity showed no zones of unstained cells and were graded as 0 or unreactive, compared with the positive control (latex rubber) that had average zones of unstained cells of 5 mm and a grade of 3 or moderate reactivity (n = 3 for each of the experimental, negative and positive controls). Genotoxicity tests were negative compared with the tin stabilized PVC, the negative control (n = 3 for each of experimental and negative and positive controls).
Extracted leachables showed no cytotoxicity, in contrast to the positive controls that gave severe grade-4 reactions causing lysis in 90% of cells (n = 3 per test group).
None of the mice tested with sodium chloride or sesame oil extracts of hydrogels or vehicle blanks (n = 5 per group) showed any mortality or evidence of systemic toxicity.
In Vitro Performance.
The hydrogels supported attachment and proliferation of corneal epithelial cells, as well as stratification. Under identical culture conditions, HCEC growth rates were identical (within 5%) on hydrogels and control tissue culture plate surfaces, reaching confluence within 4 days. Nerve overgrowth and ingrowth were also observed (not shown).
Implantation and Clinical Evaluation.
Sutures were removed at 3 weeks after surgery. Slit lamp examination of both rabbit and porcine corneas showed re-epithelialization within the first week. Although a mild haze was initially observed, only one of the total of 24 surgical corneas showed a slight haze at 6 months after surgery and none of the implants showed any sign of inflammation or rejection over this period. In the rabbit series, at 1 week after surgery, the epithelium was beginning to stratify but had not reached full thickness. At 1 month after surgery (Figs. 3A 3B) , rabbit H&E-stained sections showed a stratified epithelium over the implant (Fig. 3B) . Sodium fluorescein showed no staining, indicating the presence of an intact epithelial barrier. By 3 months after surgery (Figs. 3C 3D) , stromal cells had migrated into the implant region (Fig. 3D) . At 6 months after surgery (Figs. 3E 3F) , sections through an implant showed a normal histologic appearance (cf. Fig. 3F ), when compared to the nonsurgical contralateral corneas (not shown). The implants were well-integrated within the host corneas. IOPs were normal throughout, and the nonsurgical endothelium showed no pathologic changes.
|
|
Measurements of corneal thickness, with or without implants, showed no statistical significance (P < 0.05) between the surgical and nonsurgical corneas, indicating that the implants were not thinning or swelling within the 6-month test period.
| Discussion |
|---|
|
|
|---|
Our EDC/NHS cross-linked collagen implants allowed ingrowth of host corneal cells and nerves as with our previous collagen-TERP hydrogels.5 The EDC/NHS cross-linked collagen implants were indistinguishable from the host stroma, as measured by haze, topographical differences and thickness changes. Hence, each implant was seamlessly integrated into the host stroma where it served as a biostable scaffold for ingrowing cells and nerves. To determine whether remodeling had occurred or not, and, if so, to what extent under different postsurgical care conditions (e.g., with or without steroid treatment), is the subject of an ongoing follow-up study. Whatever the case may be, we found no statistically significant differences in corneal stromal thickness between the surgical corneas and contralateral nonsurgical ones at 6 months after surgery in the healthy rabbits and pigs studied. As a step toward clinical testing, implants in animals with diseased corneas will be evaluated next.
Although there have been many previous attempts at development of corneal implants,4 only AlphaCor devices (CooperVision Surgical, Inc., Lake Forest, CA) are in clinical use.24 These pHEMA-based, core-skirt keratoprostheses support neither epithelialization nor innervation.24 All other implants to date have this same limitation.4 In contrast, our WSC cross-linked porcine collagen implants offer a simple methodology for easy fabrication of implants, or for production of temporary patches to repair perforations.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication October 12, 2005; revised December 14, 2005; accepted March 7, 2006.
Disclosure: Y. Liu (P); L. Gan, None; D.J. Carlsson, OSI/CooperVision (F, P); P. Fagerholm, None; N. Lagali, None; M.A. Watsky, None; R. Munger, OSI/CooperVision (F); W.G. Hodge, None; D. Priest, OSI/CooperVision (F); M. Griffith, OSI/CooperVision (F, P)
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: May Griffith, University of Ottawa Eye Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa ON K1H 8L6, Canada; mgriffith{at}ohri.ca.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. V. Patel, J. C. Erie, J. W. McLaren, and W. M. Bourne Keratocyte Density and Recovery of Subbasal Nerves After Penetrating Keratoplasty and in Late Endothelial Failure Arch Ophthalmol, December 1, 2007; 125(12): 1693 - 1698. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S. Lagali, M. Griffith, N. Shinozaki, P. Fagerholm, and R. Munger Innervation of Tissue-Engineered Corneal Implants in a Porcine Model: A 1-Year In Vivo Confocal Microscopy Study Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3537 - 3544. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |